Drug Profile
Paclitaxel - Cheplapharm Arzneimittel
Alternative Names: BMS-181339; BMY 45622; NSC-673089; TaxolLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Developer Bristol-Myers Squibb; Cheplapharm Arzneimittel; Merck Sharp & Dohme Corp.; Policlinico Universitario Agostino Gemelli; University of Washington
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Gastric cancer; Kaposi's sarcoma; Non-small cell lung cancer; Ovarian cancer
- Phase II Cervical cancer
- Discontinued Bladder cancer; Cancer metastases; Endometrial cancer; Head and neck cancer; Leukaemia; Lung cancer; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Pleural effusion; Prostate cancer; Sarcoma; Small cell lung cancer; Testicular cancer
Most Recent Events
- 01 Mar 2022 Cheplapharm Arzneimittel acquires paclitaxel from Bristol-Myers Squibb
- 18 Feb 2021 Phase-II clinical trials in Cervical cancer (Neoadjuvant therapy, Combination therapy, Late-stage disease) in Italy (IV) (NCT04238988)
- 06 Jan 2020 Discontinued - Phase-II for Head and neck cancer (Late-stage disease, Recurrent) in Japan (IV) (Bristol-Myers Squibb website, January 2020)